SLRX: Salarius Pharmaceuticals Inc Company Value to Net Income

Salarius Pharmaceuticals (SLRX) develops cutting-edge therapies for rare oncological diseases, focusing on the modification of gene activity within tumors. The business model relies on the full outsourcing of molecule synthesis and testing to external contractors. Close partnerships with CRO centers eliminate production risks, and the current metric stands at -1.10. This daily price chart for the company is provided below for detailed analysis.

Price to Earnings Ratio: Salarius Pharmaceuticals (SLRX) for 07/04/2022 - 01/08/2026

Comprehensive metric breakdowns and analytics for Salarius Pharmaceuticals Inc (SLRX)

- share price and expert price forecast:

Price Performance Chart Salarius|SLRX - Consensus Target

- market capitalization information:

Market Value Salarius Pharmaceuticals Inc|SLRX - Enterprise Value

- balance sheet net asset value indicators:

Accounting Value per Share Salarius Pharmaceuticals|SLRX - Company Net Assets|Market Capitalization to Book Value Ratio salariuspharma.com|SLRX - Aggregate Company Assets

- debt and solvency information:

- company profitability and valuation multiples indicators:

SLRX - Net Profit|Projected Future Earnings Salarius Pharmaceuticals|SLRX - Price to Earnings Ratio|Future Price to Earnings Multiple Salarius|SLRX - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Salarius Pharma|SLRX - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Salarius Pharmaceuticals|SLRX - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months salariuspharma.com|SLRX - Net earnings per share growth this year|Expected earnings per share trend next year Salarius Pharmaceuticals

- issuer revenue and sales details:

SLRX - Company Revenue|Company Expected Revenue Salarius Pharmaceuticals, Inc.|SLRX - P/S Multiple|Forward Price to Sales Salarius Pharmaceuticals Inc|SLRX - Sales Growth YoY (TTM)

Comprehensive company analysis:Salarius Pharmaceuticals

Flagship merchandise of Salarius Pharmaceuticals, Inc.

The P/E ratio reflects the market value of one ruble of net profit, determining the degree of asset overvaluation. The calculation algorithm links current capitalization with future earnings expectations, reacting to the cost of borrowed capital. By analyzing changes in the P/E multiple, an investor can see the impact of interest rates on business valuation. For Salarius Pharmaceuticals (SLRX), this indicator accounts for the potential for monopoly pricing power over innovative oncology drugs. Patent protection allows the market to price in high future margins into the stock value.

Key competitors